Astrazeneca (AZN) Change in Taxes (2009 - 2026)

Astrazeneca's Change in Taxes history runs 18 years deep, the most recent figure standing at -$526.0 million for Q1 2026.

• In Q1 2026, Change in Taxes fell 44.9% year-over-year to -$526.0 million; the TTM figure through Mar 2026 stood at -$3.0 billion (down 12.11% YoY), while the FY2025 annual figure was -$2.8 billion, down 3.45% from the prior year.
• Change in Taxes for Q1 2026 stood at -$526.0 million, up from -$652.0 million in the prior quarter.
• The five-year high for Change in Taxes was -$225.0 million in Q1 2023, with the low at -$1.2 billion in Q2 2025.
• The 5-year median for Change in Taxes is -$644.0 million (2025), against an average of -$629.8 million.
• The sharpest annual moves came in 2024 and 2025: Change in Taxes tumbled 91.11% in 2024, then increased 15.58% in 2025.
• Astrazeneca's Change in Taxes stood at -$778.0 million in 2022, then declined by 7.46% to -$836.0 million in 2023, then rose by 7.66% to -$772.0 million in 2024, then gained by 15.54% to -$652.0 million in 2025, then grew by 19.33% to -$526.0 million in 2026.
• Business Quant data shows AZN's Change in Taxes at -$526.0 million in Q1 2026, -$652.0 million in Q4 2025, and -$644.0 million in Q3 2025.